A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)

被引：0
|
作者：
Beaufils, M. [1 ]
Mailliez, A. [2 ]
Sfumato, P. [3 ]
Vicier, C. [1 ]
Gross, M. Provansal [1 ]
Guerin, M. [1 ]
Chanez, B. [1 ]
Kotecki, N. [4 ]
Widemann, A. [5 ]
Panzolato, S. [6 ]
Chammard, A. Boyer [7 ]
Andre, P. [8 ]
Paturel, C. L.
Gouarne, C.
Awada, A. H.
Boher, J. M. [3 ]
Goncalves, A. [1 ]
机构：
[1] IPC Inst Paoli Calmettes, Med Oncol Dept, Marseille, France
[2] Ctr Oscar Lambret, Med Oncol Dept, Marseille, France
[3] IPC Inst Jules Bordet, Dept Clin Res, Brussels, Belgium
[4] Inst Jules Bordet, Oncol Med Dept, Brussels, Belgium
[5] Innate Pharma, Clin Pharmacol, Marseille, France
[6] Innate Pharma, Clin Operat, Marseille, France
[7] Innate Pharma, Marseille, France
[8] Innate Pharma, Res & Drug Dev, Marseille, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003P
引用
收藏
页码：S682 / S683
页数：2
相关论文
共 50 条
  • [1] First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
    Johanna Bendell
    Patricia LoRusso
    Michael Overman
    Anne M. Noonan
    Dong-Wan Kim
    John H. Strickler
    Sang-We Kim
    Stephen Clarke
    Thomas J. George
    Peter S. Grimison
    Minal Barve
    Manik Amin
    Jayesh Desai
    Trisha Wise-Draper
    Steven Eck
    Yu Jiang
    Anis A. Khan
    Yuling Wu
    Philip Martin
    Zachary A. Cooper
    Nairouz Elgeioushi
    Nancy Mueller
    Rakesh Kumar
    Sandip Pravin Patel
    Cancer Immunology, Immunotherapy, 2023, 72 : 2443 - 2458
  • [2] First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Overman, Michael
    Noonan, Anne M.
    Kim, Dong-Wan
    Strickler, John H.
    Kim, Sang-We
    Clarke, Stephen
    George, Thomas J.
    Grimison, Peter S.
    Barve, Minal
    Amin, Manik
    Desai, Jayesh
    Wise-Draper, Trisha
    Eck, Steven
    Jiang, Yu
    Khan, Anis A.
    Wu, Yuling
    Martin, Philip
    Cooper, Zachary A.
    Elgeioushi, Nairouz
    Mueller, Nancy
    Kumar, Rakesh
    Patel, Sandip Pravin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2443 - 2458
  • [3] A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas
    Zhang, Qingyuan
    Liu, Aiguo
    Shi, Jianhua
    Cai, Qingqing
    Qu, Zerui
    Liu, Sijun
    Song, Yuqin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
    Diaz, Luis A., Jr.
    Coughlin, Christina M.
    Weil, Susan C.
    Fishel, Jean
    Gounder, Mrinal M.
    Lawrence, Susan
    Azad, Nilofer
    O'Shannessy, Daniel J.
    Grasso, Luigi
    Wustner, Jason
    Ebel, Wolfgang
    Carvajal, Richard D.
    CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1281 - 1288
  • [5] Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
    Tolcher, Anthony W.
    Gordon, Michael
    Mahoney, Kathleen M.
    Seto, Anna
    Zavodovskaya, Marianna
    Hsueh, Chia-Hsiang
    Zhai, Shuyan
    Tarnowski, Thomas
    Jurgensmeier, Juliane M.
    Stinson, Susanna
    Othman, Ahmed A.
    Chen, Tianling
    Strauss, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [6] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
    Lakhani, Nehal
    Orloff, Marlana
    Fu, Siqing
    Liu, Ying
    Wang, Yan
    Zhou, Hui
    Lin, Kedan
    Liu, Fang
    Yan, Shuling
    Patnaik, Amita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A180 - A180
  • [7] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
    Siu, Lillian L.
    Burris, Howard
    Le, Dung T.
    Hollebecque, Antoine
    Steeghs, Neeltje
    Delord, Jean-Pierre
    Hilton, John
    Barnhart, Bryan
    Sega, Emanuela
    Sanghavi, Kinjal
    Klippel, Anke
    Hedvat, Cyrus
    Hilt, Ed
    Donovan, Mark
    Gipson, Adrianna
    Basciano, Paul
    Postelnek, Jennifer
    Zhao, Yue
    Perez, Raymond P.
    Carvajal, Richard D.
    CANCER RESEARCH, 2018, 78 (13)
  • [10] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
    Naing, A.
    Goel, S.
    Curti, B.
    Weise, A.
    Eder, J. P.
    Marshall, S.
    Morehouse, C.
    Li, X.
    Karakunnel, J. J.
    Infante, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345